Walleye Capital
APRE icon

Walleye Capital’s Aprea Therapeutics APRE Stock Holding History

Walleye Capital’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-80,000
Closed -$376K – 5395
2023
Q4 		$376K Sell
80,000
-2,356
-3% -$9.64K ﹤0.01% 3167
2023
Q3 		$345K Sell
82,356
-11,271
-12% -$41.1K ﹤0.01% 3118
2023
Q2 		$295K Buy
93,627
+364
+0.4% +$1.36K ﹤0.01% 2820
2023
Q1 		$415K Buy
+93,263
New +$689K 0.01% 1859
2021
Q3 		– Sell
-4,947
Closed -$483K – 1581
2021
Q2 		$483K Sell
4,947
-977
-16% -$90.3K 0.02% 762
2021
Q1 		$604K Buy
5,924
+884
+18% +$103K 0.04% 486
2020
Q4 		$496K Buy
+5,040
New +$2.4M 0.03% 481

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Walleye Capital's APRE Position: Q1 2024 in Review

Walleye Capital sold out of Aprea Therapeutics (APRE) in Q1 2024, closing a stake of 80,000 shares — an estimated $376K sold.

Walleye Capital first reported a position in APRE in Q4 2020 and held it in 7 quarters. The position peaked at $604K in Q1 2021. 24 funds tracked by Wall St. Rank hold APRE as of Q1 2024.

  • Walleye Capital reported no remaining Aprea Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 80,000 Aprea Therapeutics shares in Q1 2024, an estimated $376K.
  • Walleye Capital first reported a position in Aprea Therapeutics in Q4 2020 and held it in 7 quarters.
  • Walleye Capital's Aprea Therapeutics position peaked at $604K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.